ClinicalTrials.gg
RecruitingNCT06613178IVACSUpdated Sep 25, 2024

Intravenous Acetaminophen After Cardiac Surgery - Definitive Study

A Phase 4 interventional study of acetaminophen in Post Operative Delirium, Post Operative Pain and Post-Op Complication, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 8 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Emergence Delirium with a site in Canada — 5 open to participants now, 6 under way, none of them phase 3. Emergence Delirium · Canada.

Planned enrollment
2nd of 12
1,100 · median 199
Started
2024
with 1 other
Phase 4
Only one
of the 16
Registered
12th of 16
by date
Lead sponsor
2 of 16
McGill University Health Centre/Research Institute of the McGill University Health Centre

Among the 16 studies in Emergence Delirium with a site in Canada, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 4, and was the 12th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

5 of the 16 studies in Emergence Delirium with a site in Canada are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Emergence Delirium with a site in Canada, or all of them as a file.
02

Study summary

Double blind, double dummy trial of the use of IV acetaminophen versus oral acetaminophen for the prevention of delirium after cardiac surgery. The underlying hypothesis is that better pain control and less use of narcotics will lead to a lower incidence of delirium from day 1 to 7 following cardiac surgery. Other important secondary outcomes are the total use of narcotics, ICU and hospital stay, improved cognitive function at 6 months and 1 year post surgery, NSAID use at each centre and associated NSAID complications.

Read the detailed description

Patients > or equal to 18 years of going for elective cardiac surgery will be randomized to receive IV either IV acetaminophen and an oral placebo acetaminophen or an IV placebo acetaminophen (saline) and oral acetaminophen every 6 hours for 48 hours after cardiac surgery. the study will be performed at 8 large Canadian cardiac surgery centres. All other therapy will be as per standard procedures (pragmatic) at the institutions including including use of their standard opioid protocol. The primary end-point is the development of delirium as assessed by Confusion Assessment Method in the Intensive Care unit (CAMICU) and the CAM on the regular floor unit for up to 7 days after surgery or discharge if it is sooner. Other measures are change from pre-operative cognitive function as assessed by the Montreal Cognitive Assessment score (MoCA) at 6 months and 1 year, numeric pain score, total opioid use, hospital and ICU length of stay. Use of opioids and pain score at 1 year also will be assessed. Patients will be stratified by site and sex.

We also will assess use of NSAID, specifically ketorolac, and any NSAID associated events.

03

Conditions studied

  • Post Operative Delirium
  • Post Operative Pain
  • Post-Op Complication
  • Post-cardiac Surgery

Keywords

  • pain
  • post-operative care
  • cardiac surgery
  • narcotic
  • acetaminophen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

greater or equal to 18

  • elective cardiac surgery
  • stable pre-operative
  • aorto-coronary bypass with or without 1 valve replacement.

Exclusion criteria

Exclusion Criteria:

Refusal by surgeon Requested late extubation by surgeon or anesthesia Intra-aortic balloon pump Mechanical cardiac support Sensitivity to acetaminophen Psychiatric history with current active treatment Alzheimer\'s disease Seizure in previous 6 months Recent history of alcohol misuse Cognitive impairment

-

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,100 participants (estimated)

Study arms

  • Active comparator
    Oral Placebo

    Subject receives active intravenous acetaminophen and oral placebo acetaminophen

    Drug: acetaminophen

  • Placebo comparator
    Oral Acetaminophen

    Subject receives placebo IV fluid (saline) and active oral acetaminophen

    Drug: acetaminophen

Interventions

  • Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded

    Also known as: placebo

06

What researchers measure

Primary outcomes

  1. post operative delirium

    measured with CAMICU or CAM

    Time frame: up to 7 days

Secondary outcomes

  1. total use of opioids

    measured for 7 days or until hospital discharge

    Time frame: up to 7 days

  2. Cognitive function at 6 months and 1 year

    Measured with Montreal Cognitive assessment score.

    Time frame: 6 months and 1 year

  3. Time in intensive care unit

    measured in hours

    Time frame: up to 7 days

  4. time in hospital

    measured in days

    Time frame: up to 7 days

  5. time to extubation

    measured in hours

    Time frame: up to 7 days

07

Study locations

4 of 8 sites recruiting
  • University of British Columbia
    Vancouver, British Columbia V6T 1Z4, Canada
    Active, not recruiting

    Not enrolling at this site.

  • University of Manitoba
    Winnipeg, Manitoba R3T2N2, Canada
    Recruiting
  • Trillium Health Centre
    Mississagua, Ontario L5B2V2, Canada
    Not yet recruiting
  • University of Ottawa
    Ottawa, Ontario K1N6N5, Canada
    Not yet recruiting
  • Sunnybroook Health Centre
    Toronto, Ontario M4N3M5, Canada
    Not yet recruiting
  • McGill Universtiy Health Centre
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Universite Montreal
    Montreal, Quebec R3T2N2, Canada
    Recruiting
  • University of Laval
    Quebec City, Quebec G1V0A6, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — If the investigators of PANDORA complete their study we would request to combine our studies in a meta-analysis

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.

Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 35 months is above that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Sep 25, 2024
StartActual
Jul 2, 2024
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 15, 2027
Last update
Sep 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06613178
Collaborators
Laval University, University of British Columbia, St. Boniface Hospital, University of Ottawa, Trillium Health Centre, Université de Montréal, Sunnybrook Health Sciences Centre
Responsible party
magder sheldon (Principle Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Sep 25, 2024
Start date
Jul 2, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Sep 25, 2024

Study contacts

Sheldon Magder, MD
Contact
sheldon.magder@mcgill.ca
5149475918

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion